Immunotherapy has emerged as a standard treatment option for multiple solid tumors.
However, most patients with pancreatic cancer (PC) do not derive a significant benefit.
Identification and analyses of exceptional responders could eventually offer hints as to why PC is resistant to immunotherapy.
